- Home
- ADPT
as of 12-12-2025 3:57pm EST
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 2.6B | IPO Year: | 2019 |
| Target Price: | $16.60 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.80 - $20.76 | Next Earning Date: | 11-05-2025 |
| Revenue: | $252,754,000 | Revenue Growth: | 42.57% |
| Revenue Growth (this year): | 50.81% | Revenue Growth (next year): | 1.17% |
AI-Powered ADPT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Adaptive Biotechnologies Corporation (ADPT)
CEO and Chairman
Avg Cost/Share
$18.94
Shares
124,998
Total Value
$2,367,462.12
Owned After
2,709,241
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$19.50
Shares
162,820
Total Value
$3,174,990.00
Owned After
216,637
SEC Form 4
CEO and Chairman
Avg Cost/Share
$19.68
Shares
35,736
Total Value
$703,284.48
Owned After
2,709,241
SEC Form 4
Chief Commercial Ofc Imm Med
Avg Cost/Share
$16.91
Shares
308,477
Total Value
$5,216,346.07
Owned After
296,791
SEC Form 4
Chief Commercial Ofc Imm Med
Avg Cost/Share
$16.54
Shares
297,925
Total Value
$4,927,679.50
Owned After
296,791
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$14.05
Shares
238
Total Value
$3,343.90
Owned After
216,637
SEC Form 4
CEO and Chairman
Avg Cost/Share
$15.00
Shares
1,867
Total Value
$28,005.00
Owned After
2,709,241
SEC Form 4
CEO and Chairman
Avg Cost/Share
$14.57
Shares
1,237
Total Value
$18,023.09
Owned After
2,709,241
SEC Form 4
Chief Scientific Officer
Avg Cost/Share
$14.82
Shares
10,000
Total Value
$148,200.00
Owned After
1,269,524
SEC Form 4
CEO and Chairman
Avg Cost/Share
$14.73
Shares
86,161
Total Value
$1,269,151.53
Owned After
2,709,241
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ROBINS CHAD M | ADPT | CEO and Chairman | Dec 1, 2025 | Sell | $18.94 | 124,998 | $2,367,462.12 | 2,709,241 | |
| PISKEL KYLE | ADPT | Chief Financial Officer | Nov 28, 2025 | Sell | $19.50 | 162,820 | $3,174,990.00 | 216,637 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Nov 26, 2025 | Sell | $19.68 | 35,736 | $703,284.48 | 2,709,241 | |
| BENZENO SHARON | ADPT | Chief Commercial Ofc Imm Med | Nov 21, 2025 | Sell | $16.91 | 308,477 | $5,216,346.07 | 296,791 | |
| BENZENO SHARON | ADPT | Chief Commercial Ofc Imm Med | Nov 20, 2025 | Sell | $16.54 | 297,925 | $4,927,679.50 | 296,791 | |
| PISKEL KYLE | ADPT | Chief Financial Officer | Nov 17, 2025 | Sell | $14.05 | 238 | $3,343.90 | 216,637 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Nov 12, 2025 | Sell | $15.00 | 1,867 | $28,005.00 | 2,709,241 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Nov 11, 2025 | Sell | $14.57 | 1,237 | $18,023.09 | 2,709,241 | |
| ROBINS HARLAN S | ADPT | Chief Scientific Officer | Nov 10, 2025 | Sell | $14.82 | 10,000 | $148,200.00 | 1,269,524 | |
| ROBINS CHAD M | ADPT | CEO and Chairman | Nov 10, 2025 | Sell | $14.73 | 86,161 | $1,269,151.53 | 2,709,241 |
Compare ADPT vs Leading Stocks
See how ADPT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ADPT Adaptive Biotechnologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.